W. Vincent Xiang
W. Vincent Xiang, PhD, MBA, Managing Partner, Founder, 7G BioVentures
Bio:
Education
- B.A. (Wharton)
- D. in Molecular Biology (SUNY@ Stony Brook)
- S. in Biology (Fudan University)
Experience
- Partner
6 Dimensional Capital
- Lead cross-border equity investments in life science innovations
- Sourced and lead 8 investments in the US, EU and China
- Managing Director, Head of International Investments and Business Development, Humanwell Healthcare Group 2013 - 2016
- Led $550M acquisition of a US specialty pharma, the largest cross border M&A deal by a Chinese healthcare company
- Leading the strategy, investment and business development in ex-China markets; Helping this $3B market cap firm further grow its $1.2B/year revenue (38.6% CAGR since 2006); Driving Humanwell into a global company in human health and wellness industry
- Bringing high quality assets/platforms into China market: screened over 4000 deals in 37 months; completed two M&A deals, two drug in-licensing deals, and three product distribution deals; Over eight live deals in late stage discussion
- Investing in developed and emerging markets for equity ownership
- In discussion with Gates Foundation and one MNC pharma for strategic partnership Managing Director, China, Burrill Life Science VC Fund 2011 - 2012
- Spearhead VC investments in emerging markets with Company’s $1.5B AUM
- Fundraising for Burrill-Fosun Healthcare Venture Fund
- Fostered technology and market innovations in China healthcare industry, through long term collaboration between Fosun Pharma and Burrill & Co (>160 combined deal flow per month) Vice President, Portfolio Manager/Analyst (Franklin Templeton Inv.) 2004 - 2011
- Invested in life science sector with bottom- up fundamental analysis; Invested global life science firms; Performance ranked top quartile among over 40 analysts in the department
- Co- managed the Franklin Biotech Discovery Fund; Ranked top quartile in 1 and 5 year periods; Selected “winners”: Pharmacyclics: 317%; Pharmion: 374%; Celgene: 171%; Genentech: 219%; Onyx: 461%; OSI: 162%; Threshold: 234%
- Invested in Chinese healthcare firms such as 3S Bio (in Shenyang, 107% return), Minray Medical (Shengzhen, 239%), BMP Sunstone (Beijing, 197%), Omnitura
(Private, Shengzhen); Screened and analyzed > 60 Chinese private and public life
science firms • Advised Chinese entrepreneurs on business development and financial management
- Vice President of Business Development (Genyous Life Sciences) 2003 - 2004
- Conducted due diligence, market research, strategic planning, and out- / in- licensing deal sourcing for the biotech startup
- Raised $23M through equity financing and partnership Investment Associate (BioAdvance) 2002 - 2003
- Established process for deal sourcing, triage, and due diligence on early stage life science startups for venture capital investment
- Built operational and financial models to assess and mitigate investment risks.
- Invested in GelFlex (Acquired by Synthe), Alteris Therapeutics (Acquired by Celldex), and Acuity Pharma (Merged WITH Opko Health) Director of Life Science Investing (Acacia Research Co.) 2000 - 2002
- Screened > 40 therapeutics, diagnostics, medical device and healthcare service companies for venture investment opportunities
- Designed deal structures, prepared term sheets and negotiated terms. Prepared investment memorandums.
- Analyzed life science stocks for PIPE, RD, or open market investing Irvington Research Fellow (Skirball Institute) 1997-1999
- Conducted bench-top research on AIDS and immunological diseases
- Licensed proprietary technology to Millennium Pharmaceuticals for milestone and royalty payments 8. Research Associate (Shanghai Biological Product Inc.) 1990 – 1992
- Developed and marketed HIV diagnostic kits with synthetic antigen in China Board Membership
- Board member, LDX Prognostic Company
Honors/Awards
1.Recipient of 3551 Talent Program in Hubei, China
2.Graduate Council Commendation to Outstanding Doctoral Students
3.Sigma Xi Chapter Award
4.Abrahams Award for Outstanding Scientific Achievement
- Co-author of a scientific paper at Science Magazine and a dozen first author papers
Membership
1.Advisor, Stanford Spark Translational Research Program
2.Founding member of Chinese executive network BayHelix Group
3.Member of Chinese-American BioPharmaceutical Society (CABS)
4.Member of Sino-American Pharmaceutical Association (SAPA)
Fluent in both Chinese and English